Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation
Open Access
- 19 May 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 7 (3), 251-260
- https://doi.org/10.1093/ehjcvp/pvaa052
Abstract
Reports of long-term oral anticoagulant (OAC) therapy for atrial fibrillation (AF) reveal highly variable, and generally suboptimal estimates of medication persistence. The objective of this review is to summarize current literature and highlight important methodological considerations for interpreting persistence research and designing studies of persistence on OAC treatment. We summarize differences in study methodology, setting, timing, treatment, and other factors associated with reports of better or worse persistence. For example, prospective compared with retrospective study designs are associated with higher reported persistence. Similarly, patient factors such as permanent AF or high stroke risk, and treatment with non-vitamin K oral antagonists relative to vitamin K antagonists are associated with higher persistence. Persistence has also been reported to be higher in Europe compared with North America and higher when the treating physician is a general practitioner compared with a specialist. We propose a framework for assessing and designing persistence studies. This framework includes aspects of patient selection, reliability and validity of measures, persistence definitions, clinical utility of measurements, follow-up periods, and analytic approaches. Differences in study design, patient selection, treatments, and factors such as the countries/regions where studies are conducted or the type of treating physician may help explain the variability in OAC persistence estimates. A framework is proposed to assess persistence studies. This may have utility to compare and interpret published studies as well as for planning of future studies.Keywords
This publication has 75 references indexed in Scilit:
- Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Journal of the American College of Cardiology, 2013
- New oral anticoagulants: discussion on monitoring and adherence should start now!Thrombosis Journal, 2013
- A new taxonomy for describing and defining adherence to medicationsBritish Journal of Clinical Pharmacology, 2012
- Effect of Herbal Consumption on Time in Therapeutic Range of Warfarin Therapy in Patients With Atrial FibrillationJournal of Cardiovascular Pharmacology, 2011
- Warfarin Discontinuation After Starting Warfarin for Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2010
- Benefits of ‘observer effects’: lessons from the fieldQualitative Research, 2010
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Adherence to MedicationThe New England Journal of Medicine, 2005
- Proportion of Different Subtypes of Stroke in ChinaStroke, 2003
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991